Celyad Stops Early-Stage Colorectal Cancer Trial Amid Reported Fatalities

Celyad Oncology SA CYAD has decided to voluntarily pause the CYAD-101-002 (KEYNOTE-B79) Phase 1b trial, a part of a collaboration with Merck & Co Inc MRK

  • The trial is evaluating the company's CYAD-101 administered concurrently with FOLFOX chemotherapy, followed by Merck's Keytruda (pembrolizumab), in refractory metastatic colorectal cancer.
  • CYAD-101 is a TCR Inhibitory Molecule (TIM)-based allogeneic NKG2D CAR T cell investigational therapy.
  • The company has received reports of two fatalities presenting similar pulmonary findings. 
  • Related: Celyad Oncology Shares Gain After Fortress Injects $32M Via Equity.
  • The company has decided to voluntarily pause the dosing and enrollment in the CYAD-101-002 trial to investigate these events. 
  • In twenty-five patients previously treated with CYAD-101 in the alloSHRINK Phase 1 trial, which evaluated the TIM-based investigational candidate for advanced mCRC, no-dose limiting toxicities were reported. 
  • Price Action: CYAD shares closed higher by 5.92% at $3.22 on Friday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!